Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00129415 · ClinicalTrials.gov registry record · Phase 1
Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions
A Phase 1 study, sponsored by University of Michigan.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00129415: Clinical Trial Phase 1 study, sponsored by University of Michigan.
NCT00129415 is a Phase 1 study that was terminated before completion, run by University of Michigan. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00129415, a Phase 1 study, was terminated before completion, sponsored by University of Michigan.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this investigation is to study the effectiveness of longer wavelength UVA1 (340-400nm) or shorter wavelength ultraviolet B \[UVB\] (290-320nm) irradiation in the treatment of inflammatory skin conditions (such as: atopic dermatitis, psoriasis, mycosis fungoides, alopecia areata, stretch marks and urticaria). This research study aims to evaluate the effectiveness of an investigational device which is similar in appearance to a "tanning bed" but which emits ultraviolet irradiation of a specific wavelength known as UVA1. This device has not been approved by the Food and Drug Administration (FDA) for general use in this country, as of yet, but it has been used quite successfully in Europe for several years in treating such conditions as scleroderma, atopic dermatitis, urticaria pigmentosa and other skin conditions. Instead of UVA1 therapy, patients may receive ultraviolet radiation of a specific wavelength known as UVB. UVA1 light is a longer wavelength and therefore a lower energy wavelength than UVB. UVB light is often the light associated with getting a sunburn since it has a higher level of energy. UVB light has been used successfully in the treatment of many skin conditions.
Interventions
- PROCEDURE UVB Irradiation
- PROCEDURE UVA1 Irradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2000-08 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Why NCT00129415 stopped before completion
NCT00129415 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which UVB Irradiation is the first listed.
NCT00129415 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00129415 about?
NCT00129415 is a clinical study titled "Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions". The purpose of this investigation is to study the effectiveness of longer wavelength UVA1 (340-400nm) or shorter wavelength ultraviolet B \[UVB\] (290-320nm) irradiation in the treatment of inflammatory skin conditions (such as: atopic dermatitis, psoriasis, mycosis fungoides, alopecia areata, stret...
What is the current status of trial NCT00129415?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2000-08. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00129415?
The interventions under investigation include: UVB Irradiation (PROCEDURE), UVA1 Irradiation (PROCEDURE).
Who is sponsoring clinical trial NCT00129415?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00129415's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia